- Home
- ISPC vs PCSA Comparison
ISPC vs PCSA Comparison
Compare ISPC & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- PCSA
- Stock Information
- Founded
- ISPC 2009
- PCSA 2011
- Country
- ISPC United States
- PCSA United States
- Employees
- ISPC N/A
- PCSA N/A
- Industry
- ISPC Precision Instruments
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- PCSA Health Care
- Exchange
- ISPC Nasdaq
- PCSA Nasdaq
- Market Cap
- ISPC 4.7M
- PCSA 4.3M
- IPO Year
- ISPC 2021
- PCSA N/A
- Fundamental
- Price
- ISPC $3.95
- PCSA $0.98
- Analyst Decision
- ISPC
- PCSA Strong Buy
- Analyst Count
- ISPC 0
- PCSA 2
- Target Price
- ISPC N/A
- PCSA $5.00
- AVG Volume (30 Days)
- ISPC 222.6K
- PCSA 911.9K
- Earning Date
- ISPC 11-07-2024
- PCSA 10-30-2024
- Dividend Yield
- ISPC N/A
- PCSA N/A
- EPS Growth
- ISPC N/A
- PCSA N/A
- EPS
- ISPC N/A
- PCSA N/A
- Revenue
- ISPC $10,390,702.00
- PCSA N/A
- Revenue This Year
- ISPC $13.82
- PCSA N/A
- Revenue Next Year
- ISPC $11.76
- PCSA N/A
- P/E Ratio
- ISPC N/A
- PCSA N/A
- Revenue Growth
- ISPC 0.74
- PCSA N/A
- 52 Week Low
- ISPC $2.76
- PCSA $0.85
- 52 Week High
- ISPC $12.20
- PCSA $10.76
- Technical
- Relative Strength Index (RSI)
- ISPC 49.75
- PCSA 45.74
- Support Level
- ISPC $2.76
- PCSA $1.13
- Resistance Level
- ISPC $4.66
- PCSA $1.50
- Average True Range (ATR)
- ISPC 0.47
- PCSA 0.14
- MACD
- ISPC -0.02
- PCSA -0.00
- Stochastic Oscillator
- ISPC 62.63
- PCSA 14.81
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).